HOME > Detail View

Detail View

Practical pharmacology for Alzheimer's disease [electronic resource]

Practical pharmacology for Alzheimer's disease [electronic resource]

Material type
E-Book(소장)
Personal Author
Kudo, Takashi.
Title Statement
Practical pharmacology for Alzheimer's disease [electronic resource] / Takashi Kudo ... [et al.].
Publication, Distribution, etc
Cham :   Springer International Publishing :   Imprint: Springer,   c2016.  
Physical Medium
1 online resource (viii, 141 p.) : ill. (some col.).
ISBN
9783319262062
요약
The wide acceptance of the amyloid cascade hypothesis has led to vigorous development of disease-modifying drugs for Alzheimer’s disease, such as amyloid vaccinations and gamma- or beta-secretase inhibitors. However, the fact that clinical trials of these drugs have not yet yielded satisfactory results has meant that for the time being patients continue to be treated only with symptomatic drugs. Currently, four such drugs are available: donepezil, galantamine, rivastigmine, and memantine. In this book, the four leading experts on each of these drugs explain their practical pharmacology with the aim of providing a sound basis for their use, which to date has been of questionable proficiency. In addition, an introductory chapter considers the basic theory of pharmacology for Alzheimer’s disease and the book closes with an overview of the ways in which symptomatic drugs are used for dementia.
General Note
Title from e-Book title page.  
Content Notes
Basic theory of pharmacology for Alzheimer’s disease -- Practical Pharmacology of Donepezil -- Practical pharmacology of Galantamine -- Practical pharmacology of Rivastigmine -- Practical Pharmacology of Memantine -- How do we use Symptomatic drugs for Dementia.
Bibliography, Etc. Note
Includes bibliographical references and index.
이용가능한 다른형태자료
Issued also as a book.  
Subject Added Entry-Topical Term
Medicine. Alzheimer's disease. Alzheimer's disease --Chemotherapy. Alzheimer's disease --Treatment. Drugs --Effectiveness.
Short cut
URL
000 00000nam u2200205 a 4500
001 000046024584
005 20200507105038
006 m d
007 cr
008 200414s2016 sz a ob 001 0 eng d
020 ▼a 9783319262062
040 ▼a 211009 ▼c 211009 ▼d 211009
050 4 ▼a RM315-334
082 0 4 ▼a 616.831 ▼2 23
084 ▼a 616.831 ▼2 DDCK
090 ▼a 616.831
245 0 0 ▼a Practical pharmacology for Alzheimer's disease ▼h [electronic resource] / ▼c Takashi Kudo ... [et al.].
260 ▼a Cham : ▼b Springer International Publishing : ▼b Imprint: Springer, ▼c c2016.
300 ▼a 1 online resource (viii, 141 p.) : ▼b ill. (some col.).
500 ▼a Title from e-Book title page.
504 ▼a Includes bibliographical references and index.
505 0 ▼a Basic theory of pharmacology for Alzheimer’s disease -- Practical Pharmacology of Donepezil -- Practical pharmacology of Galantamine -- Practical pharmacology of Rivastigmine -- Practical Pharmacology of Memantine -- How do we use Symptomatic drugs for Dementia.
520 ▼a The wide acceptance of the amyloid cascade hypothesis has led to vigorous development of disease-modifying drugs for Alzheimer’s disease, such as amyloid vaccinations and gamma- or beta-secretase inhibitors. However, the fact that clinical trials of these drugs have not yet yielded satisfactory results has meant that for the time being patients continue to be treated only with symptomatic drugs. Currently, four such drugs are available: donepezil, galantamine, rivastigmine, and memantine. In this book, the four leading experts on each of these drugs explain their practical pharmacology with the aim of providing a sound basis for their use, which to date has been of questionable proficiency. In addition, an introductory chapter considers the basic theory of pharmacology for Alzheimer’s disease and the book closes with an overview of the ways in which symptomatic drugs are used for dementia.
530 ▼a Issued also as a book.
538 ▼a Mode of access: World Wide Web.
650 0 ▼a Medicine.
650 0 ▼a Alzheimer's disease.
650 0 ▼a Alzheimer's disease ▼x Chemotherapy.
650 0 ▼a Alzheimer's disease ▼x Treatment.
650 0 ▼a Drugs ▼x Effectiveness.
700 1 ▼a Kudo, Takashi.
856 4 0 ▼u https://oca.korea.ac.kr/link.n2s?url=http://dx.doi.org/10.1007/978-3-319-26206-2
945 ▼a KLPA
991 ▼a E-Book(소장)

Holdings Information

No. Location Call Number Accession No. Availability Due Date Make a Reservation Service
No. 1 Location Main Library/e-Book Collection/ Call Number CR 616.831 Accession No. E14020947 Availability Loan can not(reference room) Due Date Make a Reservation Service M

Contents information

Table of Contents

CONTENTS
1 Basic Theory of Pharmacology for Alzheimer’s Disease / Takashi Kudo = 1
 1.1 From the First Report of Alzheimer’s Disease to Its Establishment as a Concept = 1
 1.2 Elucidating the Formation of Neurofi brillary Changes = 4
 1.3 The Acetylcholine Hypothesis = 5
 1.4 The Amyloid Hypothesis = 6
 1.5 Development of Disease-Modifying Drugs (DMDs) Based on the Amyloid Hypothesis = 9
  1.5.1 Amyloid Vaccination = 9
  1.5.2 γ-/β-Secretase Inhibitors = 9
 1.6 Paradigm Shift of the Dementia Pathology Hypothesis = 13
  1.6.1 The Pathology of Abnormal Protein Accumulation Commonly Seen in Dementia = 13
  1.6.2 Endoplasmic Reticulum (ER) Stress and Dementia = 16
 References = 22
2 The Practical Pharmacology of Donepezil / Takashi Kudo = 27
 2.1 Introduction = 27
  2.1.1 ACh and Donepezil = 28
 2.2 Effects Against AD = 29
  2.2.1 Effects on Cardinal Symptoms in Mild to Moderate AD = 29
  2.2.2 Effects on Cardinal Symptoms in Advanced AD = 29
  2.2.3 Effects on the Biological and Psychological Symptoms of Dementia (BPSD) and on Caretaker Burden = 29
  2.2.4 Effects on Slowing Disease Progression = 30
 2.3 Effects Against Vascular Dementia = 30
 2.4 Effects Against Dementia with Lewy Bodies = 31
  2.4.1 Intracerebral ACh Nerves = 31
  2.4.2 Donepezil Effects Against DLB = 31
 2.5 Clinical Use = 32
 References = 32 
3 Galantamine for Alzheimer’s Disease and Alzheimer’s Disease with Cerebrovascular Disease / Kenneth L. Davis = 35
 3.1 Introduction = 35
 3.2 Nicotinic Enhancement = 35
  3.2.1 Peripheral Cholinergic Effects = 36
  3.2.2 Cognitive Profi le = 36
  3.2.3 Neuroprotection = 37
  3.2.4 Aβ Clearance = 39
 3.3 Human Clinical Data = 40
  3.3.1 Biomarkers = 40
  3.3.2 Mortality = 43
  3.3.3 Cognitive and Functional Outcomes = 45
  3.3.4 Galantamine and Memantine = 47
  3.3.5 Sleep Disturbance = 48
  3.3.6 Cholinesterase Inhibitor Withdrawal = 50
  3.3.7 Tau = 53
  3.3.8 Long-Term Outcomes in MCI = 54
  3.3.9 Switch Studies = 55
 References = 57
4 Practical Pharmacology of Rivastigmine / Rafael Blesa Gonzalez ; Ignacio Flores ; Roser Ribosa-Nogué = 63
 4.1 Alzheimer’s Defi nition and Treatment Lines = 63
 4.2 Biochemical and Physiological Aspects of Acetylcholine = 64
  4.2.1 Introduction = 64
  4.2.2 Acetylcholine Synthesis and Mechanism of Action = 64
  4.2.3 Acetylcholine Receptors and Actions = 64
  4.2.4 Central Nervous System Cholinergic Pathways = 65
  4.2.5 Functions of Acetylcholine in the Central Nervous System = 65
  4.2.6 Cholinergic Susceptibility in Aging Brain = 67
 4.3 Cholinergic Hypothesis in Alzheimer’s Disease = 67
  4.3.1 Loss of Cholinergic Activity = 67
  4.3.2 Role of Acetylcholine in Learning and Memory = 68
  4.3.3 Questioning the Cholinergic Hypothesis = 69
  4.3.4 Corroborating the Cholinergic Hypothesis = 70
  4.3.5 Reformulating the Cholinergic Hypothesis = 71
 4.4 The Interplay of Cholinergic Function and Alzheimer’s Pathology= 71
  4.4.1 Cholinergic Agonists and Amyloid Precursor Protein Processing = 71
  4.4.2 Acetylcholinesterase and Butyrylcholinesterase Relationship with Beta-Amyloid = 72
  4.4.3 Cholinergic Agonists and Tau Protein = 72
  4.4.4 Beta-Amyloid and Cholinergic Function = 73
 4.5 Enhancing Cholinergic Transmission as a Therapy of Alzheimer’s Disease = 73
 4.6 Acetylcholinesterase Inhibitors = 74
 4.7 Pharmacodynamic Properties of Rivastigmine = 75
 4.8 Pharmacokinetic Properties of Rivastigmine = 77
  4.8.1 Absorption and Distribution = 77
  4.8.2 Metabolism and Elimination = 78
  4.8.3 Special Populations = 79
 4.9 Clinical Evidence Supporting the Use of Rivastigmine = 79
  4.9.1 Cognitive Function = 80
  4.9.2 Behavioral Symptoms = 82
  4.9.3 Activities of Daily Living = 83
  4.9.4 Quality of Life of Patients and Carers = 83
  4.9.5 Physician-Rated Overall Impression Tests = 84
  4.9.6 Incidence of Adverse Events = 84
 4.10 Safety and Tolerability = 89
  4.10.1 Risk of Overdose and Death = 90
 4.11 Rivastigmine Effi cacy Compared with Other Cholinesterase Inhibitors = 90
 4.12 Rivastigmine in Clinical Practice = 91
 4.13 Present and Future of Rivastigmine = 92
 References = 93
5 Practical Pharmacology of Memantine / David G. Wilkinson = 105
 5.1 Introduction = 105
  5.1.1 Glutamate and Memantine = 105
  5.1.2 Effects of Memantine on Neurodegeneration = 106
 5.2 Memantine in Vascular Dementia = 107
 5.3 Memantine in AD = 108
  5.3.1 Clinical Trials = 108
  5.3.2 Moderately Severe AD = 108
  5.3.3 Mild to Moderate AD = 110
  5.3.4 Responder Analyses = 111
  5.3.5 Safety and Tolerability = 113
 5.4 Effects of Memantine in Combination with ChEIs = 113
 5.5 Clinical Use = 114
 References = 116
6 How Do We Use Symptomatic Drugs to Treat Dementia? / Takashi Kudo = 119
 6.1 Introduction = 119
 6.2 Characteristics of Symptomatic Drugs = 119
  6.2.1 Donepezil = 119
  6.2.2 Galantamine = 121
  6.2.3 Rivastigmine = 122
  6.2.4 Memantine = 123
 6.3 WFSBP Guidelines for the Treatment of Dementia = 125
  6.3.1 The Preventive Effects of Symptomatic Drugs = 125
  6.3.2 Indications for Symptomatic Drugs = 125
  6.3.3 Selection of Drugs and Their Dosage = 126
  6.3.4 Start and End of Drug Administration and Monitoring = 126
  6.3.5 Concomitant Therapy = 126
 6.4 Use of Different Symptomatic Drugs to Suit Different Situations Based on the Guidelines Released by Japan’s Six Relevant Academic Societies = 126
  6.4.1 Guidelines Issued by Japan’ Six Relevant Academic Societies = 126
  6.4.2 Policies on Using Symptomatic Drugs = 127
  6.4.3 Selection of Drugs = 128
 6.5 The Overviews of Symptomatic Drugs in AD Drug Guidelines = 131
  6.5.1 Use of Anti-dementia Drugs to Treat Diseases Other Than AD = 131
  6.5.2 Future Tasks and Challenges = 131
 References = 134
Index = 137

New Arrivals Books in Related Fields